The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 08, 2021

Filed:

Nov. 09, 2016
Applicant:

Cellbion Co., Ltd, Seoul, KR;

Inventors:

Jae Min Jeong, Seoul, KR;

Sung-Hyun Moon, Seoul, KR;

Yun-Sang Lee, Seoul, KR;

Assignee:

Cellbion Co., Ltd, Seoul, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 51/04 (2006.01); C07D 257/02 (2006.01); A61P 35/00 (2006.01); G01N 33/60 (2006.01); A61K 31/41 (2006.01); G01N 33/574 (2006.01); C07D 255/02 (2006.01); C07F 5/00 (2006.01);
U.S. Cl.
CPC ...
A61K 51/044 (2013.01); A61K 31/41 (2013.01); A61K 51/0402 (2013.01); A61K 51/0482 (2013.01); A61K 51/0497 (2013.01); A61P 35/00 (2018.01); C07D 255/02 (2013.01); C07D 257/02 (2013.01); C07F 5/003 (2013.01); G01N 33/574 (2013.01); G01N 33/60 (2013.01);
Abstract

The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.


Find Patent Forward Citations

Loading…